$EVOK
Evoke Pharma Inc Stock $evok

$evok Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000156459022028943 Filed on August 10, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$832.1K	$461.8K	$418.4K
YoY Change	-10.57%	95.15%	362.7%
Cost Of Revenue	$89.78K	$67.77K	$22.76K
YoY Change	53.63%	-0.7%	-62.07%
Gross Profit	$742.3K	$394.0K	$395.6K
YoY Change	-14.87%	134.0%	1218.73%
Gross Profit Margin	89.21%	85.33%	94.56%
Selling, General & Admin	$2.614M	$2.315M	$2.405M
YoY Change	-0.78%	8.08%	2.86%
% of Gross Profit	352.2%	587.56%	607.93%
Research & Development	$40.39K	$191.5K	$41.72K
YoY Change	-50.56%	-1.92%	-84.98%
% of Gross Profit	5.44%	48.59%	10.54%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.745M	$2.574M	$2.470M
YoY Change	-1.1%	7.02%	-7.88%
Operating Profit	-$1.913M	-$2.113M	-$2.051M
YoY Change	3.67%	-2.6%	-20.82%
Interest Expense	$126.0K	$124.7K	-$122.5K
YoY Change	0.0%	0.0%	-199.31%
% of Operating Profit
Other Income/Expense, Net	-$101.3K	-$120.7K	$0.00
YoY Change	-18.69%	-0.74%	-100.0%
Pretax Income	-$2.014M	-$2.233M	-$2.174M
YoY Change	2.25%	-2.5%	-16.72%
Income Tax
% Of Pretax Income
Net Earnings	-$2.014M	-$2.233M	-$2.174M
YoY Change	2.26%	-2.5%	-16.57%
Net Earnings / Revenue	-242.02%	-483.63%	-519.54%
Basic Earnings Per Share	-$0.60	-$0.71	-$0.80
Diluted Earnings Per Share	-$0.60	-$0.71	-$795.8K
COMMON SHARES
Basic Shares Outstanding	3.343M	3.157M	2.731M
Diluted Shares Outstanding	3.343M	3.157M	2.731M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.35M	$13.45M	$7.701M
YoY Change	10.84%	-19.56%	-57.66%
Cash & Equivalents	$12.40M	$13.50M	$7.700M
Short-Term Investments
Other Short-Term Assets	$11.55K	$11.55K	$627.4K
YoY Change	0.0%	-96.38%	1.19%
Inventory	$220.3K	$268.3K	$278.8K
Prepaid Expenses		$307.9K
Receivables	$675.0K	$365.6K	$418.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.26M	$14.40M	$9.026M
YoY Change	14.27%	-17.56%	-52.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$153.7K	$0.00	$0.00
YoY Change	212.85%	-100.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$153.7K	$0.00	$0.00
YoY Change	212.85%	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$13.26M	$14.40M	$9.026M
Total Long-Term Assets	$153.7K	$0.00	$0.00
Total Assets	$13.41M	$14.40M	$9.026M
YoY Change	15.11%	-17.96%	-53.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.021M	$824.5K	$944.5K
YoY Change	92.39%	58.86%	36.88%
Accrued Expenses	$857.3K	$528.7K	$412.2K
YoY Change	-0.3%	-25.16%	-25.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.878M	$1.353M	$1.357M
YoY Change	35.06%	-78.29%	-78.29%
LONG-TERM LIABILITIES
Long-Term Debt	$5.000M	$5.000M	$5.000M
YoY Change	0.0%	0.0%	0.0%
Other Long-Term Liabilities	$999.6K	$860.2K	$735.6K
YoY Change	105.57%	138.8%	206.49%
Total Long-Term Liabilities	$6.000M	$5.860M	$5.736M
YoY Change	9.36%	9.33%	9.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.878M	$1.353M	$1.357M
Total Long-Term Liabilities	$6.000M	$5.860M	$5.736M
Total Liabilities	$7.878M	$7.213M	$7.092M
YoY Change	14.56%	-37.77%	-38.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$113.8M	-$111.8M
YoY Change	7.65%
Common Stock	$119.4M	$119.0M
YoY Change	8.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.533M	$7.191M	$1.934M
YoY Change
Total Liabilities & Shareholders Equity	$13.41M	$14.40M	$9.026M
YoY Change	15.11%	-17.96%	-53.22%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.014M	-$2.233M	-$2.174M
YoY Change	2.26%	-2.5%	-16.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.101M	-$1.374M	-$1.615M
YoY Change	-81.32%	-9.24%	-45.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	7.123M	171.5K
YoY Change	-100.0%	15518.2%	-98.69%
NET CHANGE
Cash From Operating Activities	-1.101M	-1.374M	-1.615M
Cash From Investing Activities
Cash From Financing Activities	0.000	7.123M	171.5K
Net Change In Cash	-1.101M	5.750M	-1.444M
YoY Change	-80.27%	-491.67%	-114.27%
FREE CASH FLOW
Cash From Operating Activities	-$1.101M	-$1.374M	-$1.615M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	880175
	evok	Cost Of Goods Sold Expenses CostOfGoodsSoldExpenses	133004
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	473054
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4480443
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2574427
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001403708
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q2	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Operating Expenses OperatingExpenses	5086501
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2112632
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.85
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3156926
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2698833
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2944183
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2647669
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	295193
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	11551
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	528665
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10573162
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	45454
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2168996
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4759445
	evok	Forgiveness Of Paycheck Protection Loan And Accrued Interest ForgivenessOfPaycheckProtectionLoanAndAccruedInterest	105130
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3910
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4705
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6174
	us-gaap	Interest Expense InterestExpense	247997
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-121647
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-136693
	us-gaap	Net Income Loss NetIncomeLoss	-4896138
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.85
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3156925
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2698833
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2944183
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2647669
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3555094
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	381061
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3548
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	171521
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2173665
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1934011
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	366924
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	145445
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7123455
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7191010
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-3214623
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	561348
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1304846
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13070154
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2605495
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	7811384
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	399411
CY2021Q2	evok	Issuance Of Common Stock From Stock Option Exercise Value IssuanceOfCommonStockFromStockOptionExerciseValue	45454
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2290643
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	5965606
	us-gaap	Net Income Loss NetIncomeLoss	-4407045
	us-gaap	Net Income Loss NetIncomeLoss	-4896138
	us-gaap	Share Based Compensation ShareBasedCompensation	747985
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	70450
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	175100
	evok	Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets	-545455
	evok	Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets	-703867
	evok	Increase Decrease In Accounts Payable And Other Current Liabilities IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities	-805318
	evok	Accrued Compensation AccruedCompensation	-9348
	evok	Accrued Compensation AccruedCompensation	394756
	evok	Accrued Interest Expense AccruedInterestExpense	247945
	evok	Accrued Interest Expense AccruedInterestExpense	248208
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2988737
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4463608
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7443969
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14375000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	148993
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1304846
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7294976
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13115608
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4306239
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8652000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9144710
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8068939
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13450949
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16720939
	us-gaap	Loans Assumed1 LoansAssumed1	105130
	evok	Entity Incorporation Month And Year Of Incorporation EntityIncorporationMonthAndYearOfIncorporation	2007-01
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13500000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.00
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-12 reverse stock split
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.00
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. </p>
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
	evok	Bad Debt Expense BadDebtExpense	0
	evok	Bad Debt Expense BadDebtExpense	0
CY2017Q4	evok	Common Stock Shares To Be Issued Value CommonStockSharesToBeIssuedValue	16000000.0
CY2021	evok	Issuance Of Common Stock From Warrant Exercise Shares IssuanceOfCommonStockFromWarrantExerciseShares	0
CY2021	evok	Class Of Warrant Or Right Number Of Securities Expired ClassOfWarrantOrRightNumberOfSecuritiesExpired	13517
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	169000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	150000
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	100000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35000
	evok	Issuance Of Common Stock From Warrant Exercise Shares IssuanceOfCommonStockFromWarrantExerciseShares	0
	evok	Class Of Warrant Or Right Number Of Securities Expired ClassOfWarrantOrRightNumberOfSecuritiesExpired	139972
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	139972
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	34.80
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	491851
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	614132
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	491851
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	614132
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2022-10-31
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	50000
CY2007Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	650000
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	366924
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	399411
	us-gaap	Share Based Compensation ShareBasedCompensation	747985
	us-gaap	Share Based Compensation ShareBasedCompensation	960759
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2500000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y2M1D
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q4	us-gaap	Inventory Net InventoryNet	185534
	evok	Cost Of Goods Sold Expenses CostOfGoodsSoldExpenses	90535
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36075
	dei	Entity Registrant Name EntityRegistrantName	EVOKE PHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8447886
	dei	Entity Address Address Line1 EntityAddressAddressLine1	420 Stevens Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 370
	dei	Entity Address City Or Town EntityAddressCityOrTown	Solana Beach
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92075
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	345-1494
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	EVOK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3343070
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13450949
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9144710
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	365643
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	307919
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	923746
CY2022Q2	us-gaap	Inventory Net InventoryNet	268334
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	334
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	272
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	119020734
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	110977835
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111830058
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107423013
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7191010
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3555094
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14404396
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	461795
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	236635
CY2022Q2	us-gaap	Assets Current AssetsCurrent	14404396
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10560734
CY2022Q2	us-gaap	Assets Assets	14404396
CY2021Q4	us-gaap	Assets Assets	10573162
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	824481
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	612295
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5860240
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5612295
CY2022Q2	us-gaap	Liabilities Liabilities	7213386
CY2021Q4	us-gaap	Liabilities Liabilities	7018068
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3343070
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3343070
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2721373
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2721373
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	11551
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12428
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	874028
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	519317
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12428
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1353146
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1405773
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	5000000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	5000000
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	860240
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	191478
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	195229
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	233194
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2315175
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2142149
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4720251
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	2405631
	us-gaap	Operating Expenses OperatingExpenses	5043980
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4163805
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3011
CY2022Q2	us-gaap	Interest Expense InterestExpense	124658
CY2021Q2	us-gaap	Interest Expense InterestExpense	124658
	us-gaap	Interest Expense InterestExpense	247945
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-120748
	us-gaap	Net Income Loss NetIncomeLoss	-4407045
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-243240
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2233380
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2290643
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2233380
	evok	Forgiveness Of Paycheck Protection Loan And Accrued Interest1 ForgivenessOfPaycheckProtectionLoanAndAccruedInterest1	-105130
	us-gaap	Share Based Compensation ShareBasedCompensation	960759
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	327056
CY2022Q2	evok	Cost Of Goods Sold Expenses CostOfGoodsSoldExpenses	67774
CY2021Q2	evok	Cost Of Goods Sold Expenses CostOfGoodsSoldExpenses	68253
	evok	Increase Decrease In Accounts Payable And Other Current Liabilities IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities	-61975

Files In Submission

Name	View Source	Status
0001564590-22-028943-index-headers.html	Edgar Link	pending
0001564590-22-028943-index.html	Edgar Link	pending
0001564590-22-028943.txt	Edgar Link	pending
0001564590-22-028943-xbrl.zip	Edgar Link	pending
evok-10q_20220630.htm	Edgar Link	pending
evok-20220630.xsd	Edgar Link	pending
evok-ex311_10.htm	Edgar Link	pending
evok-ex312_6.htm	Edgar Link	pending
evok-ex31_476.htm	Edgar Link	pending
evok-ex321_7.htm	Edgar Link	pending
evok-ex322_8.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ghx2sofxlltq000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
evok-20220630_def.xml	Edgar Link	unprocessable
evok-20220630_lab.xml	Edgar Link	unprocessable
evok-20220630_pre.xml	Edgar Link	unprocessable
evok-10q_20220630_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
evok-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVOK
Evoke Pharma Inc Stock $evok

2022 Q3 Form 10-Q Financial Statement

#000156459022028943 Filed on August 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVOK Evoke Pharma Inc Stock $evok

2022 Q3 Form 10-Q Financial Statement

#000156459022028943 Filed on August 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVOK
Evoke Pharma Inc Stock $evok